<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Expression of Prominin 1/CD133 is associated with poor prognosis and chemoresistance in several types of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was, therefore, to evaluate Prominin 1/CD133 expression in colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> after short-term preoperative treatment by <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> (<z:chebi fb="1" ids="35475">NSAIDs</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients aimed at curative operation for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> were randomized to receive <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> (<z:chebi fb="0" ids="49662">indomethacin</z:chebi> 50 mg x2 or <z:chebi fb="0" ids="41423">celecoxib</z:chebi> 100 mg x2) three days preoperatively </plain></SENT>
<SENT sid="3" pm="."><plain>Antisecretory prophylaxis (esomeprasol 40 mg x1) was provided to <z:hpo ids='HP_0000001'>all</z:hpo> patients and served as sham intake </plain></SENT>
<SENT sid="4" pm="."><plain>CD133 expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue was also assessed in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from Dukes' B patients selected for either long or short postoperative survival </plain></SENT>
<SENT sid="5" pm="."><plain>No patients received perioperative chemoradiotherapy </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> tissue was collected at surgery for quantification of <z:chebi fb="2" ids="33699">mRNAs</z:chebi> (Prom1 and Wnt4) by qPCR </plain></SENT>
<SENT sid="7" pm="."><plain>Immunohistochemistry stained for CD133, Ep-CAM, CD34 and CD45 </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="15551">PGE2</z:chebi> content in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue was determined </plain></SENT>
<SENT sid="9" pm="."><plain>Transcript of CD133 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue was lower in patients treated with <z:chebi fb="1" ids="35475">NSAIDs</z:chebi> (0.28 ± 0.07 vs. 0.51 ± 0.08; p&lt;0.03) as well as some other stem cell-related transcripts </plain></SENT>
<SENT sid="10" pm="."><plain>In treated patients 36% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> stained positive for CD133 compared to 71% in sham-treated control patients (p&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>Short survivors with Dukes' B <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> displayed 78% CD133 expression as compared to 33% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in long-term survivors (p&lt;0.002) </plain></SENT>
<SENT sid="12" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> tissue <z:chebi fb="0" ids="26338">PGE</z:chebi>(2) content was negatively related to patient survival </plain></SENT>
<SENT sid="13" pm="."><plain>Our results show that short-term preoperative <z:chebi fb="1" ids="35475">NSAID</z:chebi> treatment downregulates <z:hpo ids='HP_0003003'>colon cancer</z:hpo> tissue expression of Prominin 1/CD133, a stem cell marker indicative of survival prognosis as confirmed </plain></SENT>
</text></document>